Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms

被引:6
作者
Ribelli, Giulia [1 ]
Simonetti, Sonia [1 ]
Iuliani, Michele [1 ]
Rossi, Elisabetta [2 ,3 ]
Vincenzi, Bruno [1 ]
Tonini, Giuseppe [1 ]
Pantano, Francesco [1 ]
Santini, Daniele [1 ]
机构
[1] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Ist Oncol Veneto IOV, Dept Immunol & Mol Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
关键词
castration resistance prostate cancer; bone microenvironment; androgen receptor; osteoblasts; matrix metalloproteinase-1; BONE METASTASES; BREAST-CANCER; GROWTH; PROGRESSION; EXPRESSION; PAR1; RESISTANCE; INVASION;
D O I
10.3389/fonc.2021.789885
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with metastatic prostate cancer frequently develop bone metastases that elicit significant skeletal morbidity and increased mortality. The high tropism of prostate cancer cells for bone and their tendency to induce the osteoblastic-like phenotype are a result of a complex interplay between tumor cells and osteoblasts. Although the role of osteoblasts in supporting prostate cancer cell proliferation has been reported by previous studies, their precise contribution in tumor growth remains to be fully elucidated. Here, we tried to dissect the molecular signaling underlining the interactions between castration-resistant prostate cancer (CRPC) cells and osteoblasts using in vitro co-culture models. Transcriptomic analysis showed that osteoblast-conditioned media (OCM) induced the overexpression of genes related to cell cycle in the CRPC cell line C4-2B but, surprisingly, reduced androgen receptor (AR) transcript levels. In-depth analysis of AR expression in C4-2B cells after OCM treatment showed an AR reduction at the mRNA (p = 0.0047), protein (p = 0.0247), and functional level (p = 0.0029) and, concomitantly, an increase of C4-2B cells in S-G2-M cell cycle phases (p = 0.0185). An extensive proteomic analysis revealed in OCM the presence of some molecules that reduced AR activation, and among these, Matrix metalloproteinase-1 (MMP-1) was the only one able to block AR function (0.1 ng/ml p = 0.006; 1 ng/ml p = 0.002; 10 ng/ml p = 0.0001) and, at the same time, enhance CRPC proliferation (1 ng/ml p = 0.009; 10 ng/ml p = 0.033). Although the increase of C4-2B cell growth induced by MMP-1 did not reach the proliferation levels observed after OCM treatment, the addition of Vorapaxar, an MMP-1 receptor inhibitor (Protease-activated receptor-1, PAR-1), significantly reduced C4-2B cell cycle (0.1 mu M p = 0.014; 1 mu M p = 0.0087). Overall, our results provide a novel AR-independent mechanism of CRPC proliferation and suggest that MMP-1/PAR-1 could be one of the potential pathways involved in this process.
引用
收藏
页数:10
相关论文
共 46 条
[1]   Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells [J].
Blaszczyk, N ;
Masri, BA ;
Mawji, NR ;
Ueda, T ;
McAlinden, G ;
Duncan, CP ;
Bruchovsky, N ;
Schweikert, HU ;
Schnabel, D ;
Jones, EC ;
Sadar, MD .
CLINICAL CANCER RESEARCH, 2004, 10 (05) :1860-1869
[2]   Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment [J].
Bock, Nathalie ;
Shokoohmand, Ali ;
Kryza, Thomas ;
Rohl, Joan ;
Meijer, Jonelle ;
Tran, Phong A. ;
Nelson, Colleen C. ;
Clements, Judith A. ;
Hutmacher, Dietmar W. .
BONE RESEARCH, 2019, 7 (1)
[3]   PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells [J].
Boire, A ;
Covic, L ;
Agarwal, A ;
Jacques, S ;
Sherifl, S ;
Kuliopulos, A .
CELL, 2005, 120 (03) :303-313
[4]   Mechanisms of resistance in castration-resistant prostate cancer (CRPC) [J].
Chandrasekar, Thenappan ;
Yang, Joy C. ;
Gao, Allen C. ;
Evans, Christopher P. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) :365-380
[5]   A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines [J].
Chay, CH ;
Cooper, CR ;
Gendernalik, JD ;
Dhanasekaran, SM ;
Chinnaiyan, AM ;
Rubin, MA ;
Schmaier, AH ;
Pienta, KJ .
UROLOGY, 2002, 60 (05) :760-765
[6]   Clinical features of metastatic bone disease and risk of skeletal morbidity [J].
Coleman, Robert E. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6243S-6249S
[7]   Thrombin receptor overexpression in malignant and physiological invasion processes [J].
Even-Ram, S ;
Uziely, B ;
Cohen, P ;
Grisaru-Granovsky, S ;
Maoz, M ;
Ginzburg, Y ;
Reich, R ;
Vlodavsky, I ;
Bar-Shavit, R .
NATURE MEDICINE, 1998, 4 (08) :909-914
[8]   Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts [J].
Forbes, K ;
Webb, MA ;
Sehgal, I .
PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (02) :148-153
[9]   Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact [J].
Gieseler, Frank ;
Ungefroren, Hendrik ;
Settmacher, Utz ;
Hollenberg, Morley D. ;
Kaufmann, Roland .
CELL COMMUNICATION AND SIGNALING, 2013, 11
[10]  
GLEAVE M, 1991, CANCER RES, V51, P3753